Bijal Shah became CEO of Guild after a stroke crisis, inspired by Taylor Swift's leadership style. She shares emotional leadership changes, managing the company through crisis, partnering with Team USA for the Olympics, and the importance of upskilling and reskilling the workforce.

Experts discuss the evolving treatment landscape in ALL and the role of immunotherapies like ADCs and CAR-T cells. They highlight the potential of targeted therapy and stopping therapy in pH positive ALL. The efficacy of cartizo for CNS infiltration and combination therapy for non-CNS EMD is discussed. The use of immunotherapies in ALL treatment is explored, including the benefits of combining therapies and optimizing immunotherapy. The effects of treatments on the immune system and tumor microenvironment in ALL are examined, including Punatine's impact on T-cells and NK-cells and the potential of LCK inhibition.

Experts from various institutions discuss Measurable Residual Disease (MRD) in the field of hemonc. They explore the role of MRD as a prognostic factor, novel technologies for MRD detection, and MRD measurement as a strategy for treatment-free survival. Recorded at several conferences, this podcast dives into the exciting realm of MRD in cancer management.